IL ILMN Illumina Inc. Loading... : Bullish and Bearish Analyst Opinions

It is an expensive stock but a pretty darn good company in genetic diagnostics, similar to Danaher.

Geromel says sequencing a person's DNA cost around $1000 twenty years ago, $500 today and will soon cost near $100. The world's largest sequencing company, Illumina, is being disrupted by China's BGI Beijing Genomics Institute, whose genetic sequencing machines are much cheaper and better than Illumina's materials. BGI began sweeping the world, but the US government banned it from the American market, which Geromel frames as protecting US corporate health rather than public health. He says Brazilian health executives are already looking to China as a health model, calling it a coming tsunami.

A news wire reports a broad list of price target raises across dozens of stocks from multiple analysts, with no directional commentary or personal market views expressed.

Illumina had a strong quarter with the stock up 50% over six months. They raised second-half guidance. The clinical business, which is over 65% of consumer revenue, is growing at a teens rate. DNA sequencing is becoming standard care for cancer profiling and monitoring, and the convergence with AI creates massive data opportunities, supporting a strong growth outlook.

A news wire reports a broad wave of price target increases across multiple stocks from various analysts, with no explicit directional calls made by the account itself.

The author notes that GRAL is a spin-off from ILMN, providing factual context without expressing a directional view on either ticker.

US pre-market movers report shows broad declines in major indices and Mag-7 stocks, with SMCI dropping 12% on a $7 billion equity raise and CBRL rising 11% on raised guidance.

Illumina rallied 22% purely on retail narrative because it was named as a stock on the Trump China trip. This speculative momentum trade can still work in the current market environment.

The author asks a rhetorical question about owning Illumina stock based on the CEO's Beijing trip, expressing curiosity rather than a directional view.

Illumina (ILMN) is a small genomics company on the list of CEOs traveling with Trump to China. It was banned from selling in China, but if Trump negotiates a deal to allow US chip exports, Illumina could re-enter the Chinese market. The stock hasn't priced this in, making it a short-term trade with asymmetric upside. I bought a small position.

Illumina (ILMN) is a small position bet on Trump's China trip leading to a deal that allows the company to re-enter the Chinese market after being blacklisted. The stock has not rallied on this news, offering asymmetric upside.

The Kobeissi Letter reports a list of CEOs joining Trump's China trip but only offers a vague bullish view on the summit's potential outcomes without explicit directional calls on any ticker.

The tweet provides a detailed technical and cross-asset analysis highlighting overbought conditions, defensive rotation, and rising VIX that suggest a cautious or bearish outlook without explicitly stating the author's own directional trade.

Illumina has found sustainable growth momentum driven by clinical genomics, especially oncology, as genomic sequencing becomes standard of care; new innovations like TruePath support long-term opportunity.